Most people think of knee osteoarthritis as a “wear-and-tear” problem—cartilage wears down, bone rubs on bone, and pain is the inevitable result. That understanding isn’t wrong, but it’s incomplete. And the incomplete picture is one reason so many patients believe their only options are pain medication or joint replacement.
Genicular artery embolization (GAE) works because it targets a part of the osteoarthritis story that conventional treatments often miss: the abnormal blood vessels that fuel chronic inflammation inside the joint. Understanding this mechanism helps explain why GAE can provide meaningful, lasting pain relief without surgery, without implants, and without altering the joint structure.
The Role of Inflammation in Knee OA Pain
Osteoarthritis was once considered a purely mechanical disease—cartilage degradation leading to structural failure. We now know it’s far more complex. Inflammation plays a central and active role in driving pain, and in many patients with mild-to-moderate OA, inflammation is the dominant source of symptoms even when cartilage loss is only moderate.
Here’s the process. As cartilage deteriorates, fragments of cartilage and other cellular debris accumulate in the joint space. The synovium—the thin membrane that lines the inside of the knee joint and produces lubricating synovial fluid—responds to these fragments by becoming inflamed (a process called synovitis). The inflamed synovium thickens, produces excess fluid (causing swelling), and releases inflammatory molecules including cytokines, VEGF (vascular endothelial growth factor), and interleukins.
This inflammation triggers the growth of new, abnormal blood vessels—a process called neovascularity or pathological angiogenesis—into the synovial tissue and surrounding structures. These new vessels are structurally abnormal: they’re leaky, poorly organized, and they bring with them sensory nerve fibers that transmit pain signals. The result is a self-reinforcing cycle: inflammation drives blood vessel growth, the new vessels bring more inflammatory cells and pain fibers, and the pain and inflammation persist even without further cartilage damage.
This is why many patients with only moderate cartilage loss on X-ray have severe pain, while some patients with significant cartilage loss have relatively little pain. The degree of neovascularity and synovial inflammation—not just the degree of structural damage—determines the patient’s pain experience.
What GAE Does: Targeting the Vascular Source
GAE interrupts this cycle at its vascular root. The procedure is performed by an interventional radiologist through a tiny arterial puncture—typically in the wrist (radial artery) or groin (femoral artery). Using real-time X-ray guidance (fluoroscopy), a microcatheter is navigated through the arterial system to the genicular arteries—the small branches that supply blood to the knee joint.
Once positioned, contrast dye is injected to create a detailed map of the blood supply to the knee. This angiogram reveals the areas of abnormal neovascularity: regions where the synovial tissue has developed a dense, pathological network of tiny blood vessels (a characteristic pattern called “synovial blush” on angiography).
Tiny biocompatible microspheres—typically 75 to 250 micrometers in diameter (smaller than a grain of sand)—are then injected through the catheter into the genicular arteries feeding these areas. The microspheres lodge in the abnormal microvessels, blocking blood flow to the inflamed tissue. Normal, healthy tissue in the knee continues to receive blood from its regular vascular supply—the embolization is selective, targeting only the pathological neovascularity.
What Happens After Embolization
With the abnormal blood supply reduced, several things happen over the following weeks and months. The inflamed synovial tissue loses its nutrient supply and begins to contract, reducing inflammation and swelling in the joint. The pain-sensing nerve fibers that traveled with the abnormal vessels are deprived of their blood supply and become less active, reducing pain transmission. Inflammatory mediators including VEGF and IL-1Ra decrease. The prospective biomarker trial from NYU showed statistically significant reductions in serum VEGF and IL-1Ra after GAE, providing biological evidence that the procedure reduces the molecular drivers of inflammation—not just the symptoms.
The clinical result: pain relief that typically begins within one to three weeks after the procedure and continues to build over one to three months as the inflammatory response resolves. In the prospective trial, patients experienced a 55.4% reduction in VAS pain scores at 12 months.
What GAE Does Not Do
Understanding what GAE doesn’t do is just as important as understanding what it does.
GAE does not regenerate cartilage. Once cartilage is lost, it does not grow back—whether you have GAE, injections, or any other currently available treatment. What GAE does is reduce the inflammatory pain that occurs around and within the joint, which can dramatically improve function and quality of life even in the presence of cartilage loss.
GAE does not alter the structure of the joint. No tissue is removed. No implants are placed. The joint anatomy is completely preserved, which means GAE does not affect your ability to have knee replacement surgery in the future if it eventually becomes necessary.
GAE is not effective for severe, end-stage OA. When the joint is severely degraded—bone-on-bone contact, significant deformity, complete loss of joint space—the pain is primarily mechanical, not inflammatory. In these cases, total knee replacement is the appropriate treatment.
The Ideal GAE Patient
GAE works best when the pain is disproportionate to the structural damage—which, as we’ve explained, is a very common scenario in mild-to-moderate osteoarthritis. The ideal candidate has Kellgren-Lawrence grade 2–3 osteoarthritis (moderate cartilage loss, but preserved joint space), persistent pain despite conservative management (PT, NSAIDs, injections), clinical or imaging evidence of synovitis or inflammation, and a desire to preserve the native joint and avoid or delay surgery.
The Bottom Line
GAE works because knee osteoarthritis is not just a cartilage problem. It’s a vascular-inflammatory problem, and GAE addresses that directly. By selectively blocking the abnormal blood vessels that fuel synovial inflammation and pain nerve fiber growth, GAE can provide clinically meaningful, evidence-based pain relief without surgery.
Frequently Asked Question
Q: What causes knee pain in osteoarthritis beyond cartilage loss?
A: Abnormal blood vessels (neovascularity) grow into the inflamed synovial lining, bringing inflammatory cells and pain-sensing nerve fibers into the joint. This vascular-inflammatory process is a major driver of OA pain.
Q: Does GAE repair cartilage?
A: No. GAE targets the inflammatory component of knee OA pain by blocking abnormal blood vessels. It does not regenerate or repair damaged cartilage.
Q: What are microspheres in GAE?
A: Microspheres are tiny biocompatible particles (typically 75–250 micrometers) injected through a catheter to block abnormal blood vessels feeding knee inflammation.
If you want to understand whether the inflammatory component of your knee pain makes you a good candidate for GAE, schedule a consultation with Dr. Albert Chun at SACMD.
Schedule a consultation: Call (240) 427-1630 or visit www.sacmd.com
Disclaimer: This article is for informational purposes only and does not constitute medical advice.
